Brawn Biotech Limited has announced a key leadership appointment, naming Ms. Rati Garg as the company's new Chief Financial Officer and Key Managerial Personnel. The appointment, which takes effect from February 1, 2026, was approved during the Board of Directors meeting held on January 30, 2026.

Board Meeting Details

The board meeting was conducted on January 30, 2026, commencing at 10:00 AM and concluding at 10:30 AM (IST). The appointment decision was made based on the recommendation of the company's Nomination and Remuneration Committee, demonstrating the structured governance process followed by the organization.

New CFO Profile and Qualifications

Ms. Rati Garg brings substantial expertise to her new role, with over 15 years of extensive experience across multiple financial domains. Her professional background encompasses financial management, cost control, budgeting, and regulatory compliance. She possesses strong expertise in financial planning and analysis (FP&A), cost optimization, and internal controls.

Areas of Expertise

The new CFO's comprehensive skill set includes:

• Financial planning and analysis (FP&A)
• Cost optimization and control
• Internal controls implementation
• Statutory and cost audits
• Taxation matters
• Corporate finance
• Budgeting and regulatory compliance

Regulatory Compliance

The appointment was announced in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company also referenced SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, ensuring full regulatory adherence.

The formal communication was submitted to BSE Limited, where Brawn Biotech Limited is listed under scrip code 530207. Company Secretary and Compliance Officer Priyanka Sharma signed the official notification, maintaining the company's commitment to transparent corporate governance and timely disclosure of material information to stakeholders.

Brawn Biotech Limited has announced the resignation of Director Mrs. Brij Bala Gupta from the company's Board of Directors, effective November 25, 2025. The pharmaceutical company provided additional details to BSE Limited on December 29, 2025, following an earlier communication dated December 22, 2025, in compliance with regulatory requirements.

Resignation Details

The resignation was formally submitted through a letter dated November 25, 2025, addressed to the Board of Directors. Mrs. Gupta's departure follows her decision to step down due to personal and professional commitments that prevent her from continuing in her directorial role.

Regulatory Compliance and Additional Disclosure

The company initially communicated the resignation to BSE Limited on December 22, 2025, but subsequently provided additional details on December 29, 2025, pursuant to BSE's request for complete documentation. The announcement was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III Part A Para 7C.

Brawn Biotech Limited acknowledged that it had inadvertently omitted to attach a copy of the resignation letter in its earlier communication, stating this was entirely unintentional. The company has now provided the complete resignation letter along with detailed reasons for the director's departure.

Director's Confirmation

Mrs. Brij Bala Gupta provided written confirmation to the company stating that there are no other material reasons for her resignation beyond those mentioned in her resignation letter. In her resignation letter, she expressed gratitude to the Board, management, and all stakeholders for the support extended during her tenure as Director.

The resignation letter specifically requested the Board to complete all necessary filings and formalities as required under regulatory provisions. Mrs. Gupta confirmed her resignation was due to pre-occupation and certain unavoidable circumstances that prevented her from continuing in her directorial capacity.

Company Information

Brawn Biotech Limited operates in the pharmaceutical sector with its registered office located at C-64, Lajpat Nagar-1, First Floor, New Delhi-110024. The company's manufacturing facility is situated at Plot No. 44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram-122001, Haryana. The company trades on BSE under scrip code 530207 with the symbol BRAWN.